NCT05103267 (TRICE-HF) is a clinical trial of Tauropace in Infection Cardiac, sponsored by Federico II University.

Who is sponsoring NCT05103267?

NCT05103267 is sponsored by Federico II University.

What drugs are being tested in NCT05103267?

Interventions in NCT05103267: Tauropace.

What condition does NCT05103267 study?

NCT05103267 studies Infection Cardiac, Heart Failure, Cardiac Implantable Electronic Device Infections, High Risk.

Is NCT05103267 still recruiting?

NCT05103267 is currently status unknown. Last updated 14 November 2022.

Last reviewed 2022-11-14 · How we verify

NCT05103267: TRICE-HF

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tauropace to Prevent Cardiac Implantable Device Infections in Heart Failure Patients

Status unknown Last updated 14 November 2022

What this trial tests

trial testing Tauropace in Infection Cardiac in 500 participants. Status unknown.

Timeline

6 June 2022

Primary endpoint
6 June 2023

6 June 2024

Quick facts

Lead sponsor	Federico II University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	500
Start date	6 June 2022
Primary completion	6 June 2023
Estimated completion	6 June 2024
Sites	1 location across Italy

Drugs / interventions tested

Tauropace

Conditions studied

Infection Cardiac — all drugs for Infection Cardiac →
Heart Failure — all drugs for Heart Failure →
Cardiac Implantable Electronic Device Infections — all drugs for Cardiac Implantable Electronic Device Infections →
High Risk — all drugs for High Risk →

Sponsor

Federico II University

Who can join

18 and older, any sex, with Infection Cardiac or Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main purpose of the study is to evaluate the ability of the Tauropace to reduce major cardiac implantable electronic device (CIED) infections through 12-months post-procedure following CIED in heart failure participants. The secondary endpoint is to prospectively characterize the performance of Tauropace in participants whose CIED system includes a transvenous RV defibrillation lead.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Federico II University trials

Trials by the same sponsor.

NCT07437690 — Fall Prevention in Older Adults in an Italian Cohort · not yet recruiting
NCT07282132 — Evaluation of Real-World Data on Ropeginterferon Alfa-2b in Patients With Polycythemia Vera: Insights From a Multicenter · not yet recruiting
NCT07280286 — Incidence of Intrauterine Adhesions After Myomectomy With Intrauterine Anti-Adhesion Gel · NA · not yet recruiting
NCT07374861 — Multicenter Study on the Evaluation of Adherence, Persistence and Efficacy of Treatment With Bempedoic Acid in Italy · recruiting
NCT07314684 — GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05103267 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Federico II University
Last refreshed: 14 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05103267.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing